Thrombosis of atypical location

How to treat patients in the era of direct oral anticoagulants?

Małgorzata K. Mimier, Dawid T. Janczak, Robert D McBane, Damon E. Houghton, Waldemar E. Wysokinski

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

In 4% of cases, venous thromboembolism (VTE) involves organ-related venous territories such as splanchnic, renal, gonadal, and cerebral venous segments, and is often called venous thromboembolism of atypical location (VTE-AL). Recommendations regarding the method, intensity, and duration of anticoagulant therapy for VTE-AL are not well established. Direct oral anticoagulants (DOACs) have been a promising alternative to vitamin K antagonists in the treatment of acute VTE. However, all major clinical trials on DOACs excluded patients with VTE-AL. Therefore, data on the use of DOACs in patients with VTE-AL are still limited to case reports and small clinical series, with a relative predominance of publications on splanchnic vein thrombosis including mesenteric, splenic, portal, and hepatic vein thrombosis. The only randomized clinical trial comparing a clinical outcome of patients with acute portal vein thrombosis ran- domized to either rivaroxaban or warfarin treatment yielded significantly impaired results due to the use of an atypical rivaroxaban dose. A prospective registration of clinical outcome for DOACs used in patients with VTE-AL, in those with VTE of typical location, and in those with VTE-AL treated with enoxaparin showed similar VTE recurrence and major bleeding rates in all 3 groups. High cancer prevalence, typical for VTE-AL, significantly impacted survival as well as VTE recurrence rates and major bleeding outcomes in this study. In general, although still limited, the results for DOAC use in VTE-AL are encouraging and we do not hesitate to use DOACs, particularly rivaroxaban or apixaban, in selected patients with VTE-AL.

Original languageEnglish (US)
Pages (from-to)604-608
Number of pages5
JournalPolish Archives of Internal Medicine
Volume128
Issue number10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Venous Thromboembolism
Anticoagulants
Thrombosis
Viscera
Portal Vein
Splenic Vein
Hemorrhage
Budd-Chiari Syndrome
Enoxaparin
Recurrence
Mesenteric Veins
Vitamin K
Warfarin
Publications
Veins
Therapeutics

Keywords

  • Cerebral venous sinus thrombosis
  • Direct oral anticoagulants
  • Gonadal vein thrombosis
  • Renal vein thrombosis
  • Splanchnic vein thrombosis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Mimier, M. K., Janczak, D. T., McBane, R. D., Houghton, D. E., & Wysokinski, W. E. (2018). Thrombosis of atypical location: How to treat patients in the era of direct oral anticoagulants? Polish Archives of Internal Medicine, 128(10), 604-608. https://doi.org/10.20452/pamw.4333

Thrombosis of atypical location : How to treat patients in the era of direct oral anticoagulants? / Mimier, Małgorzata K.; Janczak, Dawid T.; McBane, Robert D; Houghton, Damon E.; Wysokinski, Waldemar E.

In: Polish Archives of Internal Medicine, Vol. 128, No. 10, 01.01.2018, p. 604-608.

Research output: Contribution to journalReview article

Mimier, Małgorzata K. ; Janczak, Dawid T. ; McBane, Robert D ; Houghton, Damon E. ; Wysokinski, Waldemar E. / Thrombosis of atypical location : How to treat patients in the era of direct oral anticoagulants?. In: Polish Archives of Internal Medicine. 2018 ; Vol. 128, No. 10. pp. 604-608.
@article{2117536017cb428296c35cfbfafa8692,
title = "Thrombosis of atypical location: How to treat patients in the era of direct oral anticoagulants?",
abstract = "In 4{\%} of cases, venous thromboembolism (VTE) involves organ-related venous territories such as splanchnic, renal, gonadal, and cerebral venous segments, and is often called venous thromboembolism of atypical location (VTE-AL). Recommendations regarding the method, intensity, and duration of anticoagulant therapy for VTE-AL are not well established. Direct oral anticoagulants (DOACs) have been a promising alternative to vitamin K antagonists in the treatment of acute VTE. However, all major clinical trials on DOACs excluded patients with VTE-AL. Therefore, data on the use of DOACs in patients with VTE-AL are still limited to case reports and small clinical series, with a relative predominance of publications on splanchnic vein thrombosis including mesenteric, splenic, portal, and hepatic vein thrombosis. The only randomized clinical trial comparing a clinical outcome of patients with acute portal vein thrombosis ran- domized to either rivaroxaban or warfarin treatment yielded significantly impaired results due to the use of an atypical rivaroxaban dose. A prospective registration of clinical outcome for DOACs used in patients with VTE-AL, in those with VTE of typical location, and in those with VTE-AL treated with enoxaparin showed similar VTE recurrence and major bleeding rates in all 3 groups. High cancer prevalence, typical for VTE-AL, significantly impacted survival as well as VTE recurrence rates and major bleeding outcomes in this study. In general, although still limited, the results for DOAC use in VTE-AL are encouraging and we do not hesitate to use DOACs, particularly rivaroxaban or apixaban, in selected patients with VTE-AL.",
keywords = "Cerebral venous sinus thrombosis, Direct oral anticoagulants, Gonadal vein thrombosis, Renal vein thrombosis, Splanchnic vein thrombosis",
author = "Mimier, {Małgorzata K.} and Janczak, {Dawid T.} and McBane, {Robert D} and Houghton, {Damon E.} and Wysokinski, {Waldemar E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.20452/pamw.4333",
language = "English (US)",
volume = "128",
pages = "604--608",
journal = "Polskie Archiwum Medycyny Wewnetrznej",
issn = "0032-3772",
publisher = "Medycyna Praktyczna",
number = "10",

}

TY - JOUR

T1 - Thrombosis of atypical location

T2 - How to treat patients in the era of direct oral anticoagulants?

AU - Mimier, Małgorzata K.

AU - Janczak, Dawid T.

AU - McBane, Robert D

AU - Houghton, Damon E.

AU - Wysokinski, Waldemar E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In 4% of cases, venous thromboembolism (VTE) involves organ-related venous territories such as splanchnic, renal, gonadal, and cerebral venous segments, and is often called venous thromboembolism of atypical location (VTE-AL). Recommendations regarding the method, intensity, and duration of anticoagulant therapy for VTE-AL are not well established. Direct oral anticoagulants (DOACs) have been a promising alternative to vitamin K antagonists in the treatment of acute VTE. However, all major clinical trials on DOACs excluded patients with VTE-AL. Therefore, data on the use of DOACs in patients with VTE-AL are still limited to case reports and small clinical series, with a relative predominance of publications on splanchnic vein thrombosis including mesenteric, splenic, portal, and hepatic vein thrombosis. The only randomized clinical trial comparing a clinical outcome of patients with acute portal vein thrombosis ran- domized to either rivaroxaban or warfarin treatment yielded significantly impaired results due to the use of an atypical rivaroxaban dose. A prospective registration of clinical outcome for DOACs used in patients with VTE-AL, in those with VTE of typical location, and in those with VTE-AL treated with enoxaparin showed similar VTE recurrence and major bleeding rates in all 3 groups. High cancer prevalence, typical for VTE-AL, significantly impacted survival as well as VTE recurrence rates and major bleeding outcomes in this study. In general, although still limited, the results for DOAC use in VTE-AL are encouraging and we do not hesitate to use DOACs, particularly rivaroxaban or apixaban, in selected patients with VTE-AL.

AB - In 4% of cases, venous thromboembolism (VTE) involves organ-related venous territories such as splanchnic, renal, gonadal, and cerebral venous segments, and is often called venous thromboembolism of atypical location (VTE-AL). Recommendations regarding the method, intensity, and duration of anticoagulant therapy for VTE-AL are not well established. Direct oral anticoagulants (DOACs) have been a promising alternative to vitamin K antagonists in the treatment of acute VTE. However, all major clinical trials on DOACs excluded patients with VTE-AL. Therefore, data on the use of DOACs in patients with VTE-AL are still limited to case reports and small clinical series, with a relative predominance of publications on splanchnic vein thrombosis including mesenteric, splenic, portal, and hepatic vein thrombosis. The only randomized clinical trial comparing a clinical outcome of patients with acute portal vein thrombosis ran- domized to either rivaroxaban or warfarin treatment yielded significantly impaired results due to the use of an atypical rivaroxaban dose. A prospective registration of clinical outcome for DOACs used in patients with VTE-AL, in those with VTE of typical location, and in those with VTE-AL treated with enoxaparin showed similar VTE recurrence and major bleeding rates in all 3 groups. High cancer prevalence, typical for VTE-AL, significantly impacted survival as well as VTE recurrence rates and major bleeding outcomes in this study. In general, although still limited, the results for DOAC use in VTE-AL are encouraging and we do not hesitate to use DOACs, particularly rivaroxaban or apixaban, in selected patients with VTE-AL.

KW - Cerebral venous sinus thrombosis

KW - Direct oral anticoagulants

KW - Gonadal vein thrombosis

KW - Renal vein thrombosis

KW - Splanchnic vein thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85055915360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055915360&partnerID=8YFLogxK

U2 - 10.20452/pamw.4333

DO - 10.20452/pamw.4333

M3 - Review article

VL - 128

SP - 604

EP - 608

JO - Polskie Archiwum Medycyny Wewnetrznej

JF - Polskie Archiwum Medycyny Wewnetrznej

SN - 0032-3772

IS - 10

ER -